Diagnos Inc., a Canadian corporation specializing in early detection of critical eye-related health issues through Artificial Intelligence, has announced an engagement with Investor Brand Network for corporate communication and awareness solutions. The one-year agreement, effective January 10, 2026, involves monthly compensation of US$6,400 payable in advance from the corporation's funds, and remains subject to acceptance by the TSX Venture Exchange.
This strategic partnership is significant as it represents a focused effort by Diagnos to strengthen its market presence and communicate its value proposition more effectively to investors and stakeholders. The company's core mission involves leveraging AI technology to provide healthcare clinicians with enhanced diagnostic tools for eye-related problems, aiming to improve accuracy, streamline workflows, and ultimately achieve better patient outcomes globally. By engaging IBN, Diagnos seeks to refine its market awareness profile with the explicit objective of maximizing shareholder value.
The engagement carries implications for investors and the healthcare technology sector. For shareholders, enhanced corporate communications could lead to greater market recognition and potentially influence the company's valuation. IBN, which operates at arm's length and holds no direct or indirect interest in Diagnos securities according to the announcement, will provide services through its specialized communications platform. This platform includes advanced wire-grade press release syndication, article and editorial syndication to over 5,000 outlets, enhanced press release optimization, and social media distribution to millions of followers.
For the healthcare technology industry, this move highlights the growing importance of strategic communication in bringing innovative medical AI solutions to market attention. Diagnos's technology represents the convergence of healthcare and artificial intelligence, a sector experiencing rapid growth and investor interest. Effective communication of such technological advancements is crucial for securing investment, forming partnerships, and ultimately ensuring these solutions reach healthcare providers and patients who can benefit from them.
The financial commitment of US$6,400 monthly underscores the company's dedication to this communications initiative. Additional information about Diagnos is available through its corporate website at https://www.diagnos.com and regulatory filings at https://www.sedarplus.com, while updates relating to the company are accessible in its newsroom at https://ibn.fm/DGNOF. The full press release detailing this engagement can be viewed at https://ibn.fm/NRVea. InvestorWire, the platform powering this dissemination, provides further information about its services at https://www.InvestorWire.com, with terms of use and disclaimers available at https://www.InvestorWire.com/Disclaimer.
